The estimated Net Worth of Tamara Elias is at least $5.22 millier dollars as of 10 September 2022. Tamara Elias owns over 2,250 units of Avinger Inc stock worth over $5,220 and over the last 4 years he sold AVGR stock worth over $0. In addition, he makes $0 as Director at Avinger Inc.
Tamara has made over 2 trades of the Avinger Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,250 units of AVGR stock worth $2,610 on 10 September 2022.
The largest trade he's ever made was exercising 45,000 units of Avinger Inc stock on 10 March 2021 worth over $52,200. On average, Tamara trades about 9,450 units every 110 days since 2021. As of 10 September 2022 he still owns at least 4,500 units of Avinger Inc stock.
You can see the complete history of Tamara Elias stock trades at the bottom of the page.
Dr. Tamara N. Elias M.D. serves as Director of the Company. From 2007-2015, Dr. Elias was a Partner with Essex Woodlands Healthcare Partners, a healthcare only growth equity firm founded in 1985 and currently with over $3 billion in funds raised to date. There she focused on medical device, healthcare services and healthcare IT investments and served on several boards, including Millennium Pharmacy Systems (sold to Pharmerica), BreatheAmerica, Influence Health (sold to Healthgrades) and ATS Medical (sold to Medtronic). Earlier in her career, Dr. Elias was a management consultant at McKinsey, advising pharmaceutical, diagnostic and device companies in R&D, product commercialization and M&A. Dr. Elias holds degrees in Biology and Anthropology from Yale University, and an M.D. from The Johns Hopkins School of Medicine. She trained as a general surgeon at Massachusetts General Hospital.
Tamara's mailing address filed with the SEC is 400, Chesapeake Drive, Redwood City, San Mateo County, California, 94063, United States.
Over the last 10 years, insiders at Avinger Inc have traded over $4,931,811 worth of Avinger Inc stock and bought 65,650 units worth $291,405 . The most active insiders traders include John B Ph D Md Simpson, James Cullen et Jeffrey M Soinski. On average, Avinger Inc executives and independent directors trade stock every 57 days with the average trade being worth of $43,246. The most recent stock trade was executed by Nabeel Paul Subainati on 22 March 2023, trading 417 units of AVGR stock currently worth $484.
avinger, inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (pad). pad is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. the company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. avinger’s current lumivascular products include the lightbox imaging console, the ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or ctos, and pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in pad patients.
Avinger Inc executives and other stock owners filed with the SEC include: